{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:10:26Z","timestamp":1784225426534,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Chiatai Qingchunbao Pharmaceutical Limited Company","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-017-2373-x","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T12:20:52Z","timestamp":1518006052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for\u00a0a cluster randomized controlled trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Jingen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9484-9819","authenticated-orcid":false,"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"2373_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","volume":"133","author":"D Mozaffarian","year":"2016","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: Heart disease and stroke statistics\u20142016 update. Circulation. 2016;133:447\u201354.","journal-title":"Circulation."},{"key":"2373_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.ehj.2004.04.024","volume":"25","author":"M Togni","year":"2004","unstructured":"Togni M, Balmer F, Pfiffner D, Maier W, Zeiher AM, Meier B. Percutaneous coronary interventions in Europe 1992\u20132001. Eur Heart J. 2004;25:1208\u201313.","journal-title":"Eur Heart J."},{"key":"2373_CR3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1056\/NEJMoa067731","volume":"356","author":"L Mauri","year":"2007","unstructured":"Mauri L, Hsieh WH, Massaro JM, Ho KK, D\u2019Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020\u20139.","journal-title":"N Engl J Med."},{"key":"2373_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","volume":"384","author":"JP Collet","year":"2014","unstructured":"Collet JP, Silvain J, Barthelemy O, Range G, Cayla G, Van Belle E, et al. Dual-antiplatelet treatment beyond 1\u00a0year after drug-eluting stent implantation (ARCTIC-Interruption): A randomised trial. Lancet. 2014;384:1577\u201385.","journal-title":"Lancet."},{"key":"2373_CR5","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","volume":"362","author":"SJ Park","year":"2010","unstructured":"Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362:1374\u201382.","journal-title":"N Engl J Med."},{"key":"2373_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","volume":"129","author":"CW Lee","year":"2014","unstructured":"Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: A randomized, controlled trial. Circulation. 2014;129:304\u201312.","journal-title":"Circulation."},{"key":"2373_CR7","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","volume":"125","author":"M Valgimigli","year":"2012","unstructured":"Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation. 2012;125:2015\u201326.","journal-title":"Circulation."},{"key":"2373_CR8","first-page":"365","volume":"37","author":"G Helft","year":"2016","unstructured":"Helft G, Steg PG, Le Feuvre C, Georges JL, Carrie D, Dreyfus X, et al. Stopping or continuing clopidogrel 12\u00a0months after drug-eluting stent placement: The OPTIDUAL randomized trial. Eur Heart J. 2016;37:365\u201374.","journal-title":"Eur Heart J."},{"key":"2373_CR9","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30\u00a0months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155\u201366.","journal-title":"N Engl J Med."},{"key":"2373_CR10","doi-asserted-by":"publisher","first-page":"h1618","DOI":"10.1136\/bmj.h1618","volume":"350","author":"EP Navarese","year":"2015","unstructured":"Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: Meta-analysis of randomised controlled trials. BMJ. 2015;350:h1618.","journal-title":"BMJ."},{"key":"2373_CR11","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","volume":"69","author":"T Palmerini","year":"2017","unstructured":"Palmerini T, Bacchi RL, Della RD, Romanello M, Feres F, Abizaid A, et al. Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting. J Am Coll Cardiol. 2017;69:2011\u201322.","journal-title":"J Am Coll Cardiol."},{"key":"2373_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S0033291706008841","volume":"37","author":"W Rossler","year":"2007","unstructured":"Rossler W, Lauber C, Angst J, Haker H, Gamma A, Eich D, et al. The use of complementary and alternative medicine in the general population: Results from a longitudinal community study. Psychol Med. 2007;37:73\u201384.","journal-title":"Psychol Med."},{"key":"2373_CR13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1353\/hpu.2011.0002","volume":"22","author":"D Su","year":"2011","unstructured":"Su D, Li L. Trends in the use of complementary and alternative medicine in the United States: 2002\u20132007. J Health Care Poor Underserved. 2011;22:296\u2013310.","journal-title":"J Health Care Poor Underserved."},{"key":"2373_CR14","first-page":"1","volume":"2013","author":"Y Jia","year":"2013","unstructured":"Jia Y, Leung S, Lee M, Cui G, Huang X, Pan F. The efficacy of Guanxinning injection in treating angina pectoris: Systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Altemat Med. 2013;2013:1\u201316.","journal-title":"Evid Based Complement Altemat Med."},{"key":"2373_CR15","doi-asserted-by":"publisher","first-page":"16235","DOI":"10.3390\/molecules200916235","volume":"20","author":"X Ma","year":"2015","unstructured":"Ma X, Ma Y, Tang J, He Y, Liu Y, Ma X, et al. The biosynthetic pathways of tanshinones and phenolic acids in Salvia miltiorrhiza. Molecules. 2015;20:16235\u201354.","journal-title":"Molecules."},{"key":"2373_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.041","volume":"220","author":"S Gao","year":"2012","unstructured":"Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. 2012;220:3\u201310.","journal-title":"Atherosclerosis."},{"key":"2373_CR17","doi-asserted-by":"publisher","first-page":"e64255","DOI":"10.1371\/journal.pone.0064255","volume":"8","author":"HH Tsai","year":"2013","unstructured":"Tsai HH, Lin HW, Lu YH, Chen YL, Mahady GB. A review of potential harmful interactions between anticoagulant\/antiplatelet agents and Chinese herbal medicines. PLoS ONE. 2013;8:e64255.","journal-title":"PLoS ONE."},{"key":"2373_CR18","first-page":"97","volume":"31","author":"M Li","year":"2004","unstructured":"Li M, Zhao C, Wong RN, Goto S, Wang Z, Liao F. Inhibition of shear-induced platelet aggregation in rat by tetramethylpyrazine and salvianolic acid B. Clin Hemorheol Microcirc. 2004;31:97\u2013103.","journal-title":"Clin Hemorheol Microcirc."},{"key":"2373_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0049-3848(01)00343-7","volume":"104","author":"M Li","year":"2001","unstructured":"Li M, Handa S, Ikeda Y, Goto S. Specific inhibiting characteristics of tetramethylpyrazine, one of the active ingredients of the Chinese herbal medicine \u2018Chuanxiong\u2019, on platelet thrombus formation under high shear rates. Thromb Res. 2001;104:15\u201328.","journal-title":"Thromb Res."},{"key":"2373_CR20","first-page":"586","volume":"10","author":"M Chen","year":"2005","unstructured":"Chen M, Shou Q, Pan Y, Zhang J, Sang R, Guan M, et al. Inhibitive and protective effects of Guanxinning tablets on platelet aggregation and vascular endothelium in qi stagnation and blood stasis rats. Chin J Clin Pharmacol Ther. 2005;10:586\u20139.","journal-title":"Chin J Clin Pharmacol Ther."},{"key":"2373_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137.","journal-title":"Ann Intern Med."},{"key":"2373_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11655-016-2400-x","volume":"23","author":"H Xu","year":"2017","unstructured":"Xu H, Chen KJ. Practical diagnostic criterion of blood stasis syndrome: Activating blood circulation committee of Chinese association of integrative medicine. Chin J Integr Med. 2017;23:243\u20134.","journal-title":"Chin J Integr Med."},{"key":"2373_CR23","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht310.P4876","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949\u20133003.","journal-title":"Eur Heart J."},{"key":"2373_CR24","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation."},{"key":"2373_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.amjcard.2012.10.030","volume":"111","author":"SR Mulukutla","year":"2013","unstructured":"Mulukutla SR, Marroquin OC, Vlachos HA, Selzer F, Toma C, Kip KE, et al. Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: From the NHLBI dynamic registry. Am J Cardiol. 2013;111:486\u201392.","journal-title":"Am J Cardiol."},{"key":"2373_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/eurheartj\/ehn480","volume":"30","author":"P Ortolani","year":"2009","unstructured":"Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, et al. Long-term effectiveness of early administration of glycoprotein IIb\/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J. 2009;30:33\u201343.","journal-title":"Eur Heart J."},{"key":"2373_CR27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jclinepi.2004.08.012","volume":"58","author":"MC Gulliford","year":"2005","unstructured":"Gulliford MC, Adams G, Ukoumunne OC, Latinovic R, Chinn S, Campbell MJ. Intraclass correlation coefficient and outcome prevalence are associated in clustered binary data. J Clin Epidemiol. 2005;58:246\u201351.","journal-title":"J Clin Epidemiol."},{"key":"2373_CR28","first-page":"482","volume":"15","author":"Y Zou","year":"2005","unstructured":"Zou Y, Ying H, Pan Y, Xu X, Wang H, Xu J, et al. Effects of Guanxinning tablet on coronary blood flow in acute myocardial ischemic Beagle dog model. Zhejiang J Integr Tradit Chin West Med. 2005;15:482\u20135.","journal-title":"Zhejiang J Integr Tradit Chin West Med."},{"key":"2373_CR29","first-page":"432","volume":"24","author":"M Wang","year":"2016","unstructured":"Wang M, Pan Y, Jin M, Xu X, Wang D, Ma Q, et al. Establishment of a zebrafish model of thrombosis and the intervention effect of Guanxinning tablet. Acta Laboratorium Animalis Scientia Sinica. 2016;24:432\u20138.","journal-title":"Acta Laboratorium Animalis Scientia Sinica."},{"key":"2373_CR30","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1097\/MLR.0b013e3181dbebcf","volume":"48","author":"R Platt","year":"2010","unstructured":"Platt R, Takvorian SU, Septimus E, Hickok J, Moody J, Perlin J, et al. Cluster randomized trials in comparative effectiveness research: Randomizing hospitals to test methods for prevention of healthcare-associated infections. Med Care. 2010;48:S52\u20137.","journal-title":"Med Care."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-2373-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T22:03:55Z","timestamp":1693519435000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-2373-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2373"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-2373-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]},"assertion":[{"value":"7 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study complies with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol and consent form have been reviewed and approved by the Ethics Committee of Xiyuan Hospital of China Academy of Chinese Medical Sciences (reference number, 2016XL010-2, 24 November 2016).Any amendment to the protocol must be approved again by the Ethics Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication of the dataset is gained from the patients at the point of recruitment, and all patients enrolled will be fully anonymous.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"93"}}